Ashenafi Shiferaw Bulle

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kian‐Huat Lim · 5 shared papers, 2020–2026 · strength 0.99
   • Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
   • Paper Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. DOI 10.1038/s41392-020-00341-1↗
   • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
2. Vikas Somani · 3 shared papers, 2024–2026 · strength 0.65
   • Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
   • Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
   • Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
3. Sapana Bansod · 3 shared papers, 2024–2026 · strength 0.65
   • Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
   • Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
   • Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
4. David G DeNardo · 3 shared papers, 2024–2026 · strength 0.65
   • Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
   • Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
   • Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
5. Ryan C Fields · 2 shared papers, 2024–2026 · strength 0.41
   • Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
   • Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
6. Paarth B. Dodhiawala · 2 shared papers, 2020–2024 · strength 0.31
   • Paper Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. DOI 10.3390/cancers12092675↗
   • Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
7. Liang‐I Kang · 1 shared paper, 2026 · strength 0.24
   • Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
8. Kian-Huat Lim · 1 shared paper, 2026 · strength 0.24
   • Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
9. Jos F. van Pelt · 2 shared papers, 2019–2020 · strength 0.20
   • Paper Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. DOI 10.1016/j.tranon.2020.01.004↗
   • Paper Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. PMID 30899378↗
10. Jeroen Dekervel · 2 shared papers, 2019–2020 · strength 0.20
    • Paper Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. DOI 10.1016/j.tranon.2020.01.004↗
    • Paper Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. PMID 30899378↗
11. Chris Verslype · 2 shared papers, 2019–2020 · strength 0.20
    • Paper Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. DOI 10.1016/j.tranon.2020.01.004↗
    • Paper Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. PMID 30899378↗
12. Eric Van Cutsem · 2 shared papers, 2019–2020 · strength 0.20
    • Paper Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. DOI 10.1016/j.tranon.2020.01.004↗
    • Paper Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. PMID 30899378↗
13. Alexander Starodub · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
14. Julien Dilly · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
15. Wungki Park · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
16. Ida Aronchik · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
17. Urszula N. Wasko · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
18. Andrew J. Aguirre · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
19. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
20. Anirban Maitra · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
21. Minal A. Barve · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
22. David S. Hong · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
23. Ignacio Garrido‐Laguna · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
24. Mallika Singh · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗
25. Alexander I. Spira · 1 shared paper, 2026 · strength 0.18
    • Paper Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategie… DOI 10.1038/s41591-026-04537-w↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.